Trial Profile
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Docetaxel
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms ROSE
- Sponsors Eli Lilly and Company (India) Pvt. Ltd; ImClone Systems
- 16 Feb 2021 Status changed from active, no longer recruiting to completed.
- 02 Jan 2020 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.